{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:46:06Z","timestamp":1791650766660,"version":"4.3.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["CAN 20 1226 PjF"],"award-info":[{"award-number":["CAN 20 1226 PjF"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006313","name":"Barncancerfonden","doi-asserted-by":"publisher","award":["PR2021-0064"],"award-info":[{"award-number":["PR2021-0064"]}],"id":[{"id":"10.13039\/501100006313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s40262-024-01382-3","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T06:03:15Z","timestamp":1717653795000},"page":"871-884","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacogenetic Testing or Therapeutic Drug Monitoring: A Quantitative Framework"],"prefix":"10.1007","volume":"63","author":[{"given":"Maddalena","family":"Centanni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Reijnhout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abel","family":"Thijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats O.","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2979-679X","authenticated-orcid":false,"given":"Lena E.","family":"Friberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"key":"1382_CR1","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/cpt.1997","volume":"109","author":"A Maloney","year":"2021","unstructured":"Maloney A. Personalized Dosing\u00a0=\u00a0Approved Wide Dose Ranges\u00a0+\u00a0Dose Titration. Clin Pharmacol Ther [Internet]. 2021;109:566\u20137. https:\/\/doi.org\/10.1002\/cpt.1997.","journal-title":"Clin Pharmacol Ther [Internet]"},{"key":"1382_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00177","author":"T Buclin","year":"2020","unstructured":"Buclin T, Thoma Y, Widmer N, Andr\u00e9 P, Guidi M, Csajka C, et al. The steps to therapeutic drug monitoring: a structured approach illustrated with imatinib [Internet]. Front Pharmacol. 2020. https:\/\/doi.org\/10.3389\/fphar.2020.00177.","journal-title":"Front Pharmacol"},{"key":"1382_CR3","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1002\/cpt.777","volume":"103","author":"SC van Dijkman","year":"2018","unstructured":"van Dijkman SC, Wicha SG, Danhof M, Della Pasqua OE. Individualized Dosing Algorithms and Therapeutic Monitoring for Antiepileptic Drugs. Clin Pharmacol Ther [Internet]. 2018;103:663\u201373. https:\/\/doi.org\/10.1002\/cpt.777.","journal-title":"Clin Pharmacol Ther [Internet]"},{"key":"1382_CR4","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S0140-6736(22)01841-4","volume":"401","author":"JJ Swen","year":"2023","unstructured":"Swen JJ, van der Wouden CH, Manson LE, Abdullah-Koolmees H, Blagec K, Blagus T, et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet (London, England). 2023;401:347\u201356.","journal-title":"Lancet (London, England)."},{"key":"1382_CR5","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/tpj.2017.21","volume":"17","author":"M Verbelen","year":"2017","unstructured":"Verbelen M, Weale ME, Lewis CM. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? Pharmacogenomics J. 2017;17:395\u2013402.","journal-title":"Pharmacogenomics J"},{"key":"1382_CR6","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.911","volume":"103","author":"U Amstutz","year":"2018","unstructured":"Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther [Internet]. 2018;103:210\u20136. https:\/\/doi.org\/10.1002\/cpt.911.","journal-title":"Clin Pharmacol Ther [Internet]"},{"key":"1382_CR7","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1161\/CIRCULATIONAHA.110.943860","volume":"123","author":"MJ Pletcher","year":"2011","unstructured":"Pletcher MJ, Pignone M. Evaluating the clinical utility of a biomarker: a review of methods for estimating health impact. Circulation. 2011;123:1116\u201324.","journal-title":"Circulation"},{"key":"1382_CR8","doi-asserted-by":"crossref","unstructured":"Vegting IL, van Beneden M, Kramer MHH, Thijs A, Kostense PJ, Nanayakkara PWB. How to save costs by reducing unnecessary testing: Lean thinking in clinical practice. Eur J Intern Med [Internet]. 2012;23:70\u20135. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0953620511001488.","DOI":"10.1016\/j.ejim.2011.07.003"},{"key":"1382_CR9","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/bcp.13119","volume":"83","author":"JF Standing","year":"2017","unstructured":"Standing JF. Understanding and applying pharmacometric modelling and simulation in clinical practice and research. Br J Clin Pharmacol. 2017;83:247\u201354. https:\/\/doi.org\/10.1111\/bcp.13119.","journal-title":"Br J Clin Pharmacol"},{"key":"1382_CR10","unstructured":"Baron KT. mrgsolve: Simulate from ODE-Based Models [Internet]. 2022. https:\/\/github.com\/metrumresearchgroup\/mrgsolve. Accessed 23 Aug 2023."},{"key":"1382_CR11","unstructured":"RStudio Team. RStudio: Integrated Development Environment for R [Internet]. Boston, MA; 2020. http:\/\/www.rstudio.com\/. Accessed 22 Nov 2022.\u00e5"},{"key":"1382_CR12","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/psp4.12507","volume":"9","author":"J Elassaiss-Schaap","year":"2020","unstructured":"Elassaiss-Schaap J, Duisters K. Variability in the log domain and limitations to its approximation by the normal distribution. CPT Pharmacometrics Syst Pharmacol [Internet]. 2020;9:245\u201357. https:\/\/doi.org\/10.1002\/psp4.12507.","journal-title":"CPT Pharmacometrics Syst Pharmacol [Internet]"},{"key":"1382_CR13","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","volume":"581","author":"KJ Karczewski","year":"2020","unstructured":"Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alf\u00f6ldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature [Internet]. 2020;581:434\u201343. https:\/\/doi.org\/10.1038\/s41586-020-2308-7.","journal-title":"Nature [Internet]."},{"key":"1382_CR14","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s10928-014-9392-y","volume":"41","author":"W Jawie\u0144","year":"2014","unstructured":"Jawie\u0144 W. Searching for an optimal AUC estimation method: a never-ending task? J Pharmacokinet Pharmacodyn. 2014;41:655\u201373.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1382_CR15","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2307\/2531089","volume":"39","author":"D Katz","year":"1983","unstructured":"Katz D, D\u2019Argenio DZ. Experimental design for estimating integrals by numerical quadrature, with applications to pharmacokinetic studies. Biometrics. 1983;39:621\u20138.","journal-title":"Biometrics"},{"key":"1382_CR16","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1111\/bcp.13901","volume":"85","author":"JA Abrantes","year":"2019","unstructured":"Abrantes JA, J\u00f6nsson S, Karlsson MO, Nielsen EI. Handling interoccasion variability in model-based dose individualization using therapeutic drug monitoring data. Br J Clin Pharmacol [Internet]. 2019;85:1326\u201336. https:\/\/doi.org\/10.1111\/bcp.13901.","journal-title":"Br J Clin Pharmacol [Internet]."},{"key":"1382_CR17","unstructured":"Hooker AC, Karlsson MO, Chen X, Assawasuwannakit P. Improved bioequivalence assessment through model-informed and model-based strategies [Internet]. [cited 2022 Feb 16]. https:\/\/www.fda.gov\/media\/138035\/download. Accessed 16 Feb 2022."},{"key":"1382_CR18","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/bcp.13838","volume":"85","author":"LM Andrews","year":"2019","unstructured":"Andrews LM, Hesselink DA, van Schaik RHN, van Gelder T, de Fijter JW, Lloberas N, et al. A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients. Br J Clin Pharmacol. 2019;85:601\u201315.","journal-title":"Br J Clin Pharmacol"},{"key":"1382_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.595219","volume":"11","author":"H Abdullah-Koolmees","year":"2020","unstructured":"Abdullah-Koolmees H, van Keulen AM, Nijenhuis M, Deneer VHM. Pharmacogenetics guidelines: overview and comparison of the DPWG, CPIC, CPNDS, and RNPGx guidelines. Front Pharmacol. 2020;11: 595219.","journal-title":"Front Pharmacol"},{"key":"1382_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00283","author":"L Klopp-Schulze","year":"2020","unstructured":"Klopp-Schulze L, Mueller-Schoell A, Neven P, Koolen SLW, Mathijssen RHJ, Joerger M, et al. Integrated data analysis of six clinical studies points toward model-informed precision dosing of tamoxifen [Internet]. Front Pharmacol. 2020. https:\/\/doi.org\/10.3389\/fphar.2020.00283.","journal-title":"Front Pharmacol"},{"key":"1382_CR21","doi-asserted-by":"publisher","unstructured":"Habtewold A, Aklillu E, Makonnen E, Yimer G, Bertilsson L, Burhenne J, et al. Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients. Antimicrob Agents Chemother. 2017;61(8):e00207\u201317. https:\/\/doi.org\/10.1128\/aac.00207-17.","DOI":"10.1128\/aac.00207-17"},{"key":"1382_CR22","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s40262-015-0289-8","volume":"54","author":"F Vandenberghe","year":"2015","unstructured":"Vandenberghe F, Guidi M, Choong E, von Gunten A, Conus P, Csajka C, et al. Genetics-based population pharmacokinetics and pharmacodynamics of risperidone in a psychiatric cohort. Clin Pharmacokinet. 2015;54:1259\u201372.","journal-title":"Clin Pharmacokinet"},{"key":"1382_CR23","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/BF03257473","volume":"51","author":"ABP van Kuilenburg","year":"2012","unstructured":"van Kuilenburg ABP, H\u00e4usler P, Schalhorn A, Tanck MWT, Proost JH, Terborg C, et al. Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy. Clin Pharmacokinet. 2012;51:163\u201374.","journal-title":"Clin Pharmacokinet"},{"key":"1382_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-023-01336-1","author":"M Centanni","year":"2023","unstructured":"Centanni M, van de Velde ME, Uittenboogaard A, Kaspers GJL, Karlsson MO, Friberg LE. Model-informed precision dosing to reduce vincristine-induced peripheral neuropathy in pediatric patients: a pharmacokinetic and pharmacodynamic modeling and simulation analysis. Clin Pharmacokinet [Internet]. 2023. https:\/\/doi.org\/10.1007\/s40262-023-01336-1.","journal-title":"Clin Pharmacokinet [Internet]."},{"key":"1382_CR25","doi-asserted-by":"publisher","unstructured":"Skiles JL, Chiang C, Li CH, Martin S, Smith EL, Olbara G, et al. CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer. Pediatr Blood Cancer. 2018;65:e26854. https:\/\/doi.org\/10.1002\/pbc.26854.","DOI":"10.1002\/pbc.26854"},{"key":"1382_CR26","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/j.1365-2141.2008.07235.x","volume":"142","author":"G L\u00f6nnerholm","year":"2008","unstructured":"L\u00f6nnerholm G, Frost B-M, Abrahamsson J, Behrendtz M, Castor A, Forestier E, et al. Vincristine pharmacokinetics is related to clinical outcome in children with standard risk acute lymphoblastic leukemia. Br J Haematol [Internet]. 2008;142:616\u201321. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07235.x.","journal-title":"Br J Haematol [Internet]"},{"key":"1382_CR27","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/psp4.12353","volume":"7","author":"RJ Keizer","year":"2018","unstructured":"Keizer RJ, ter Heine R, Frymoyer A, Lesko LJ, Mangat R, Goswami S. Model-Informed Precision Dosing at the Bedside: Scientific Challenges and Opportunities. CPT Pharmacometrics Syst Pharmacol [Internet]. 2018;7:785\u20137. https:\/\/doi.org\/10.1002\/psp4.12353.","journal-title":"CPT Pharmacometrics Syst Pharmacol [Internet]"},{"key":"1382_CR28","doi-asserted-by":"publisher","unstructured":"Lunenburg CATC, Henricks LM, Guchelaar H-J, Swen JJ, Deenen MJ, Schellens JHM, et al. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time. Eur J Cancer [Internet]. 2016;54:40\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2015.11.008.","DOI":"10.1016\/j.ejca.2015.11.008"},{"key":"1382_CR29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/cpt.113","volume":"98","author":"KA Birdwell","year":"2015","unstructured":"Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clin Pharmacol Ther. 2015;98:19\u201324.","journal-title":"Clin Pharmacol Ther"},{"key":"1382_CR30","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ctrv.2015.01.002","volume":"41","author":"L Binkhorst","year":"2015","unstructured":"Binkhorst L, Mathijssen RHJ, Jager A, van Gelder T. Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping. Cancer Treat Rev. 2015;41:289\u201399.","journal-title":"Cancer Treat Rev"},{"key":"1382_CR31","doi-asserted-by":"publisher","first-page":"6300","DOI":"10.1158\/1078-0432.CCR-16-1967","volume":"22","author":"SLW Koolen","year":"2016","unstructured":"Koolen SLW, Bins S, Mathijssen RHJ. Individualized tamoxifen dose escalation\u2014letter. Clin Cancer Res [Internet]. 2016;22:6300. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1967.","journal-title":"Clin Cancer Res [Internet]"},{"key":"1382_CR32","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1080\/17425255.2017.1395413","volume":"13","author":"LM Andrews","year":"2017","unstructured":"Andrews LM, Li Y, De Winter BCM, Shi Y-Y, Baan CC, Van Gelder T, et al. Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients. Expert Opin Drug Metab Toxicol. 2017;13:1225\u201336.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1382_CR33","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/FTD.0b013e3181f0634c","volume":"32","author":"S Cabrera Figueroa","year":"2010","unstructured":"Cabrera Figueroa S, Fern\u00e1ndez de Gatta M, Hern\u00e1ndez Garc\u00eda L, Dom\u00ednguez-Gil Hurl\u00e9 A, Bustos Bernal C, Sep\u00falveda Correa R, et al. The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy. Ther Drug Monit. 2010;32:579\u201385.","journal-title":"Ther Drug Monit"},{"key":"1382_CR34","doi-asserted-by":"publisher","unstructured":"de Leon J. Personalizing dosing of risperidone, paliperidone and clozapine using therapeutic drug monitoring and pharmacogenetics. Neuropharmacology [Internet]. 2020;168:107656. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.05.033.","DOI":"10.1016\/j.neuropharm.2019.05.033"},{"key":"1382_CR35","doi-asserted-by":"publisher","unstructured":"Uittenboogaard A, Neutel CLG, Ket JCF, Njuguna F, Huitema ADR, Kaspers GJL, et al. Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy in Children with Cancer: A Systematic Review and Meta-Analysis. Cancers (Basel). 2022;14(3):612. https:\/\/doi.org\/10.3390\/cancers14030612.","DOI":"10.3390\/cancers14030612"},{"key":"1382_CR36","doi-asserted-by":"publisher","unstructured":"van de Velde ME, Panetta JC, Wilhelm AJ, van den Berg MH, van der Sluis IM, van den Bos C, et al. Population pharmacokinetics of vincristine related to infusion duration and peripheral neuropathy in pediatric oncology patients. Cancers . 2020;12(7):1789. https:\/\/doi.org\/10.3390\/cancers12071789.","DOI":"10.3390\/cancers12071789"},{"key":"1382_CR37","doi-asserted-by":"publisher","unstructured":"Henricks LM, Opdam FL, Beijnen JH, Cats A, Schellens JHM. DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update. Ann Oncol [Internet]. 2017;28:2915\u201322. https:\/\/doi.org\/10.1093\/annonc\/mdx411.","DOI":"10.1093\/annonc\/mdx411"},{"key":"1382_CR38","unstructured":"Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol [Internet]. 2018;19:1459\u201367. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1470204518306867."},{"key":"1382_CR39","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1007\/s40262-023-01296-6","volume":"62","author":"S Baklouti","year":"2023","unstructured":"Baklouti S, Comets E, Gandia P, Concordet D. Multivariate Exact Discrepancy: A New Tool for PK\/PD Model Evaluation. Clin Pharmacokinet. 2023;62:1599\u2013609.","journal-title":"Clin Pharmacokinet"},{"key":"1382_CR40","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00228-010-0857-7","volume":"66","author":"G Gervasini","year":"2010","unstructured":"Gervasini G, Ben\u00edtez J, Carrillo JA. Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. Eur J Clin Pharmacol. 2010;66:755\u201374.","journal-title":"Eur J Clin Pharmacol"},{"key":"1382_CR41","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/sj.clpt.6100188","volume":"81","author":"F Sj\u00f6qvist","year":"2007","unstructured":"Sj\u00f6qvist F, Eliasson E. The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants. Clin Pharmacol Ther. 2007;81:899\u2013902.","journal-title":"Clin Pharmacol Ther"},{"key":"1382_CR42","doi-asserted-by":"publisher","first-page":"783","DOI":"10.2165\/00003088-200140110-00001","volume":"40","author":"MH Ensom","year":"2001","unstructured":"Ensom MH, Chang TK, Patel P. Pharmacogenetics: the therapeutic drug monitoring of the future? Clin Pharmacokinet. 2001;40:783\u2013802.","journal-title":"Clin Pharmacokinet"},{"key":"1382_CR43","doi-asserted-by":"publisher","unstructured":"Agema BC, Buijs SM, Sassen SDT, M\u00fcrdter TE, Schwab M, Koch BCP, et al. Toward model-informed precision dosing for tamoxifen: a population-pharmacokinetic model with a continuous CYP2D6 activity scale. Biomed Pharmacother [Internet]. 2023;160:114369. https:\/\/doi.org\/10.1016\/j.biopha.2023.114369.","DOI":"10.1016\/j.biopha.2023.114369"},{"key":"1382_CR44","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","volume":"41","author":"M Brunet","year":"2019","unstructured":"Brunet M, van Gelder T, \u00c5sberg A, Haufroid V, Hesselink DA, Langman L, et al. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Ther Drug Monit. 2019;41:261\u2013307.","journal-title":"Ther Drug Monit"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01382-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-024-01382-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01382-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T02:40:37Z","timestamp":1719974437000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-024-01382-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1382"],"URL":"https:\/\/doi.org\/10.1007\/s40262-024-01382-3","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"5 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Uppsala University. The Swedish Cancer Society (CAN 20 1226 PjF). The Swedish Childhood Cancer Fund (PR2021-0064). The computations were enabled by resources provided by the Swedish National Infrastructure for Computing (SNIC) at Uppsala University, partially funded by the Swedish Research Council through grant agreement no. 2022-06725 and no. 2018-05973.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding and Acknowledgements"}},{"value":"MC, NR, AT, LEF, MOK, and LEF declare no competing interests for this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The data that support the findings of this study are not openly accessible, but can be made available from the authors upon reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"The code used for data analysis and statistical modeling is available upon request from the corresponding author, LEF.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"This simulation study does not involve the use of human subjects, patient data, or identifiable information. As such, formal ethical approval was not sought for this research.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Given the nature of the simulation study, there were no human participants involved and no consent to participate was necessary.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"This simulation study does not involve human subjects or their data, and explicit consent for publication from individuals is not applicable. However, any contributions from co-authors have been acknowledged, and their consent for publication has been obtained.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"MC, NR, LEF, and MOK wrote the manuscript. MC, NR, LEF, and MOK designed the research and analyzed the data. MC and NR performed the research.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}